Clinical Trial Update: Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a parathyroid hormone attenuation therapy in patients undergoing hemodialysis with secondary hyperparathyroidism has completed, per s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• PTH attenuation therapy (investigational)

Snippet

Sponsor: Pathalys Pharma | Conditions: Secondary Hyperparathyroidism, End Stage Kidney Disease | Phase 3 | Status: COMPLETED